Description
Addressing these issues, Visiongain s Fourth Annual Recombinant Antibodies conference showcases how such goals are being met by leading experts. Whether your interests lie in basic, pre-clinical, translational or clinical research, business diversification, licensing or partnering, attending this meeting will empower you to: Better utilise, deploy and evaluate in silico tools during early-phase research Overcome protein aggregation in clinical development Enhance physicochemical and pharmacokinetic properties to prolong or decrease circulating antibody half-life and exposure Optimise the potency of IgG molecules for ADCC, ADCP or CDC applications Examine prospects for second and third generation therapeutics including Fab, scFv, bispecific, and alternative scaffold technologies Employ improved HTS tools and choose the right species for in vivo trials Decrease production and processing costs and boost antibody expression, yield, delivery and safety
Visitors profile
Presidents, Chief Executive Officers, Chief Scientific Officers, Vice Presidents, Professors, Heads, Directors, Principal/Senior Scientists and Managers/Team Leaders of: Antibody design, production and development Recombinant DNA/molecular biotechnolo
